As CTCL Staging and Treatment Evolves, Treatment-Associated Rash Remains a Crucial Consideration: With Brad Haverkos, MD
Season 17 Episode 34 · Jun 18, 10:30 PM
Share
Subscribe
Brad Haverkos, MD, discusses evolving management and treatment adherence strategies in cutaneous T-cell lymphoma.
In today’s episode, we welcomed Brad Haverkos, MD, to discuss evolving management and treatment adherence strategies in cutaneous T-cell lymphoma (CTCL). Dr Haverkos is an associate professor of medicine-hematology at the University of Colorado in Anschutz School of Medicine in Aurora. In the exclusive interview, Dr Haverkos outlined treatment approaches across early-stage and advanced CTCL, identified strategies for identifying disease progression in this patient population, and spoke about how clinicians manage mogamulizumab-kpkc (Poteligeo)-associated rash.
